WO2019232665A1 - Composé d'indolizine thiolisé à activité anticancéreuse et son dérivé - Google Patents

Composé d'indolizine thiolisé à activité anticancéreuse et son dérivé Download PDF

Info

Publication number
WO2019232665A1
WO2019232665A1 PCT/CN2018/000246 CN2018000246W WO2019232665A1 WO 2019232665 A1 WO2019232665 A1 WO 2019232665A1 CN 2018000246 W CN2018000246 W CN 2018000246W WO 2019232665 A1 WO2019232665 A1 WO 2019232665A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
substituted
unsubstituted
pharmaceutically acceptable
stereoisomer
Prior art date
Application number
PCT/CN2018/000246
Other languages
English (en)
Chinese (zh)
Inventor
曹华
李彬
陈伟鑫
Original Assignee
广东药科大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广东药科大学 filed Critical 广东药科大学
Publication of WO2019232665A1 publication Critical patent/WO2019232665A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present invention relates to a class of thioindazines, or stereoisomers thereof, or pharmaceutically acceptable salts or solvates thereof.
  • the present invention further relates to a pharmaceutical composition containing at least the aforementioned compound for use in the treatment of cancer.
  • Cancer is one of the important diseases that seriously threaten human health, and its treatment and prevention have attracted widespread attention.
  • the current treatment methods include surgical resection, radiation therapy, and chemical drug treatment.
  • chemical drug treatment is still the main method.
  • chemical drugs used in the clinical treatment of cancer such as platinums, nitrogen mustards, triazoles, etc., but most drugs are limited in their application due to their high toxicity, many adverse reactions, and low bioavailability. Therefore, finding effective and low-toxic anticancer drugs has become one of the key research topics in the field of medicinal chemistry.
  • the invention relates to a new class of indazine compounds, which can effectively inhibit various types of cancers or tumors.
  • the invention provides a thioindazine compound and its derivative with anticancer activity.
  • the purpose of the present invention is to use the compound for treating various cancers or tumors, or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof.
  • the invention also provides methods and intermediates for preparing the compounds of the invention or their stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of the invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof.
  • the present invention also provides a method for treating a tumor or cancer, which comprises administering to a host a therapeutically effective amount of at least one compound of the present invention, or a stereoisomer, tautomer, or pharmaceutically acceptable Salts, solvates or prodrugs thereof.
  • a preferred embodiment is the treatment of various tumors or cancers.
  • the invention also provides the compound or a stereoisomer, tautomer, medicament for use in therapy
  • the invention also provides the compound or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof, for preparing a medicine for treating cancer.
  • the present invention provides a compound of general formula selected from the compounds of formula I, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, as shown below:
  • R 1 -R 3 are independently selected from hydrogen, deuterium, halogen, -CN, -C (O) -OEt, -SR 0 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1- 6 haloalkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-10 cycloalkyl, substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted 5-10 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, or substituted or substituted containing 1-4 heteroatoms selected from N, O and S Unsubstituted 5-10 membered heteroaryl;
  • R 0 is independently selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 haloalkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2- 6 alkynyl, substituted or unsubstituted C 3-10 cycloalkyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted containing 1-4 heteroatoms selected from N, O and S 5-10 membered heterocyclic ring, or substituted or unsubstituted 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O and S.
  • said substituted means that the corresponding group is replaced by halogen, NH 2 , OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10
  • halogen NH 2 , OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10
  • One or more of cycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O and S are substituted.
  • the aryl group is selected from phenyl, naphthyl, anthracenyl or phenanthryl.
  • the heteroaryl group is selected from the group consisting of indolyl, benzothiazolyl, pyrazolopyridyl, benzoisothiazolyl, triazolopyridyl, indazopyridyl, benzoxazolyl, Triazolopyridyl, indazinopyridyl, pyridopyrazinyl, quinazolinyl, pyridopyrazinyl, benzooxadiazyl, benzothiadiazolyl, benzoindazinyl.
  • the invention also provides a method for preparing the compound, which includes the following steps:
  • Substituted nitrogen indene and substituted mercaptans are prepared in an oil bath
  • composition comprising the above-mentioned compound as shown in I, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable adjuvant, carrier or diluent.
  • the dosage form of the composition is selected from plain tablets, film-coated tablets, sugar-coated tablets, enteric-coated tablets, dispersible tablets, capsules, granules, oral solutions or oral suspensions.
  • the compound represented by I, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof can be used for preparing a medicine for treating tumors or cancers.
  • the tumors or cancers are gastric cancer, cervical adenocarcinoma, Colon cancer, lung cancer, liver cancer, glioma, esophageal cancer, bowel cancer, nasopharyngeal cancer, breast cancer, lymphoma, kidney cancer, pancreatic cancer, bladder cancer, ovarian cancer, uterine cancer, bone cancer, gallbladder cancer, lip cancer , Melanoma, tongue cancer, laryngeal cancer, blood cancer, prostate cancer, brain tumor, squamous cell carcinoma, skin cancer, hemangioma, lipoma, cervical cancer and thyroid cancer.
  • the invention also provides methods and intermediates for preparing the compounds of the invention, their stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs.
  • the present invention also provides a method for treating tumors or cancers (or a compound of the present invention or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof for use in the preparation of a medicament for treating these diseases Use), including administering to a host a therapeutically effective amount of at least one compound of the present invention, or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, according to a therapeutic need.
  • the invention also provides methods of treating diseases (or the use of a compound of the invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for treating these diseases) Including administering to a patient a therapeutically effective amount of a compound of formula I, wherein the disease is gastric cancer, cervical adenocarcinoma, colon cancer, lung cancer, liver cancer, glioma, esophageal cancer, bowel cancer, nasopharyngeal cancer, breast Cancer, lymphoma, kidney cancer, pancreatic cancer, bladder cancer, ovarian cancer, uterine cancer, bone cancer, gallbladder cancer, lip cancer, melanoma, tongue cancer, laryngeal cancer, blood cancer, prostate cancer, brain tumor, squamous cell carcinoma, Skin cancer, hemangiomas, lipomas, cervical cancer and thyroid cancer.
  • the disease is gastric cancer, cervical adenocarcinoma, colon cancer, lung cancer,
  • the invention also provides a method for treating a disease, which comprises administering to a patient a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, in combination with other therapeutic agents.
  • the invention also provides the compounds or their stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs for use in therapy.
  • the compound of formula I is selected from an exemplary compound or a combination of exemplary compounds or other specific embodiments herein.
  • the invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) and one or more active ingredients.
  • alkyl as used herein includes both branched and straight chain saturated hydrocarbon groups having a specific number of carbon atoms.
  • C 1-10 alkyl (or alkylene) is intended to be C1, C2, C3, C4, C5, C6, C7, C8, C9 and C10 alkyl.
  • C 1-6 alkyl means an alkyl group having 1 to 6 carbon atoms.
  • An alkyl group may be unsubstituted or substituted such that one or more of its hydrogen atoms are replaced by other chemical groups.
  • alkyl examples include, but are not limited to, methyl (Me), ethyl (Et), propyl (such as n-propyl and isopropyl), butyl (such as n-butyl, isobutyl, tert-butyl) , Pentyl (such as n-pentyl, isopentyl, neopentyl) and their analogs.
  • alkenyl is a hydrocarbon that includes both a straight or branched chain structure and has one or more carbon-carbon double bonds that occur at any stable point in the chain.
  • C 2-6 alkenyl (or alkenylene) is intended to include C2, C3, C4, C5 and C6 alkenyl.
  • alkenyl include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl , 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, 4-methyl-3-pentenyl, and the like.
  • alkynyl is a hydrocarbon that includes both a linear or branched structure and has one or more carbon-carbon triple bonds that occur at any stable point in the chain.
  • C 2-6 alkynyl (or alkynylene) is intended to include C2, C3, C4, C5, and C6 alkynyl; such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, and Its analog.
  • alkenyl, alkynyl, alkylene, alkenylene or alkynylene these groups are substituted with one to three alkyl substituents as described above.
  • substituted refers to the replacement of any one or more hydrogen atoms on a specified atom or group with a selected specified group, provided that the general valence of the specified atom is not exceeded.
  • 2 hydrogen atoms on the atom are replaced.
  • Ketone substituents are not present on the aromatic fragments.
  • substituents are named to the central structure. For example, it is understood that when (cycloalkyl) alkyl is a possible substituent, the point of attachment of the substituent to the central structure is in the alkyl moiety.
  • a stable compound or stable structure implies that the compound is sufficiently stable when isolated from the reaction mixture with useful purity, and is subsequently formulated to form an effective therapeutic agent.
  • the present compound does not comprise N- halogen, S (O) 2 H, or S (O) H group.
  • cycloalkyl refers to cycloalkyl and includes mono-, bi- or polycyclic systems.
  • C 3-7 cycloalkyl is intended to include C3, C4, C5, C6 and C7 cycloalkyl.
  • Examples of cycloalkyl include, but are not limited to, cyclopropyl, butyl, cyclopentyl, cyclohexyl, norbornyl, and the like.
  • carbocycle or “carbocycle residue” refers to any stable 3, 4, 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12, or 13- Two-membered bi- or tricyclic, which may be saturated, partially unsaturated, unsaturated or aromatic.
  • carbocyclic rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, pentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, adamantyl, Cyclooctyl, cyclooctenyl, cyclooctadiene, [3.3.0] bicyclooctane, [4.3.0] bicyclononane, [4.4.0] bicyclodecane, [2.2.2] bicyclooctane, Fluorenyl, phenyl, naphthyl, indanyl, adamantyl, anthracenyl, and tetrahydronaphthyl (naphthyl).
  • bridged rings are also included in the definition of carbocyclic rings (such as [2.2.2] bicyclooctane). Unless otherwise stated, preferred carbocyclic rings are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl. When the term “carbocycle” is used, it is intended to include “aryl”. Bridged rings occur when one or more carbon atoms connect two non-adjacent carbon atoms. Preferred bridges are one or two carbon atoms. It is pointed out that the bridge always converts a single ring into a double ring. When the ring is bridged, the substituents of the ring also exist on the bridge.
  • aryl refers to a monocyclic or bicyclic aromatic hydrocarbon group having 6 to 12 carbon atoms in the ring portion, such as phenyl and naphthyl, each of which may be substituted.
  • halogen refers to chlorine, bromine, fluorine and iodine.
  • haloalkyl refers to a substituted alkyl group having one or more halogen substituents.
  • haloalkyl includes mono, bis and trifluoromethyl.
  • heteroaryl refers to substituted and unsubstituted aromatic 5- or 6-membered monocyclic groups, 9- or 10-membered bicyclic groups, and 11 to 14-membered tricyclic groups having at least one ring in at least one ring One heteroatom (O, S or N), said heteroatom-containing ring preferably having 1, 2 or 3 heteroatoms selected from O, S and N.
  • Each ring of a heteroaryl-containing heteroaryl group may contain one or two oxygen or sulfur atoms and / or from 1 to 4 nitrogen atoms, provided that the total number of heteroatoms in each ring is 4 or less, and each Each ring has at least one carbon atom.
  • Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazoline, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, furyl, thienyl, oxadiazolyl , Pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, and the like.
  • Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxenyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinyl Phenyl, benzimidazolyl, benzopyranyl, indolazinyl, benzofuranyl, chromone, coumarin, benzopyranyl, fluorinyl, quinoxalinyl, indazole Group, pyrrolopyridyl, fluoropyridyl, dihydroisoindolyl, tetrahydroquinolinyl and the like.
  • salt refers to the formation of acidic and / or basic salts with inorganic and / or organic acids and bases.
  • salt may include zwitterions (internal salts), such as when the compound of formula I contains a basic fragment such as an amine or pyridine or an imidazole ring, and an acid fragment such as a carboxylic acid.
  • Pharmaceutically acceptable (ie, non-toxic, physiological (Acceptable) salts are preferred, such as acceptable metal and amine salts, where the cations do not significantly contribute to toxicity or the biological activity of the salt.
  • the salts of the compound of formula I can be formed as a compound of formula I with a certain amount of acid or base, such as an equivalent amount, in a medium such as where the salt can be precipitated or in its aqueous medium, and then frozen. Dry action.
  • Exemplary acid addition salts include acetates (such as with acetic acid or trihaloacetic acid, such as trifluoroacetic acid), adipic acid salts, alginates, ascorbates, aspartates, benzoates , Benzene sulfonate, hydrogen sulfate, borate, butyrate, citrate, camphor, camphor sulfonate, cyclopentanoate, digluconate, dodecyl sulfate, Ethylsulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride (formed with hydrochloric acid), hydrobromide (formed with hydrobromic acid) , Hydroiodate, 2-hydroxyethanesulfonate, lactate, maleate (formed with maleic acid), mesylate (formed with methanesulfonic acid), 2-naphthal
  • Exemplary basic salts include ammonium, alkali metal salts such as sodium, lithium, and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; barium, zinc, and aluminum salts; salts with organic bases (such as organic amines) such as trioxane Based amines such as triethylamine, procaine, dibenzylamine, N-benzyl- ⁇ -phenethylamine, 1-diphenylhydroxymethylamine, N, N′-bisbenzylethylenediamine, dehydroabietylamine , N-ethylpiperidine, benzylamine, dicyclohexylamine or similar pharmaceutically acceptable amines and salts with amino acids such as arginine, lysine and the like.
  • organic bases such as organic amines
  • trioxane Based amines such as triethylamine, procaine, dibenzylamine, N-benzyl- ⁇ -phenethylamine, 1-diphenyl
  • Basic nitrogen-containing groups can be quaternized with reagents such as lower alkyl halides (such as methyl, ethyl, propyl and butyl chloride, bromine and iodide), dialkyl sulfates (such as dimethyl, Diethyl, dibutyl and dipentyl sulfate), long-chain halides (e.g. decyl, dodecyl, tetradecyl and octadecyl chloride, bromine and iodide), aralkyl halides Substances (such as benzyl and phenethyl bromide) and other substances.
  • Preferred salts include monohydrochloride, bisulfate, mesylate, phosphate or nitrate.
  • phrases "pharmaceutically acceptable” refers to those compounds, materials, compositions, and / or dosage forms that, within the scope of sound medical evaluation, are suitable for use in contact with human and animal tissues without additional toxicity, irritation, An allergic reaction or other problem or complication with a reasonably reasonable benefit / risk ratio.
  • pharmaceutically acceptable salt refers to a derivative of a disclosed compound in which the parent compound is modified with an acid or a basic salt thereof.
  • pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic groups such as amines; and base or organic salts of acid groups such as carboxylic acids.
  • Pharmaceutically acceptable salts include traditional non-toxic salts or parent compounds that form quaternary ammonium salts, such as from non-toxic inorganic or organic acids.
  • these traditional non-toxic salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, and nitric acid; and salts prepared from organic acids such as acetic acid, propionic acid, succinic acid, and glycolic acid , Stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2- Ethoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid and isethionic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, and
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound containing a basic or acidic fragment by conventional chemical methods.
  • these salts can be prepared from a suitable base or acid in the free acid or base form and stoichiometric ratio of these compounds in water or an organic solvent, or a mixture of both; typically, non-aqueous vehicles such as ether, ethyl acetate , Ethanol, isopropanol or acetonitrile are preferred.
  • Stereoisomers can include compounds of substituted optical isomers through one or more chiral atoms, and optical isomer compounds through restricted rotation of one or more bonds (atropisomers).
  • the definition of the compounds of the invention includes all possible stereoisomers and mixtures thereof. These include, in particular, racemic forms and isolated optical isomers with particular activity. Racemic forms are resolved by physical methods, such as distributed crystallization, separation or crystallization of stereoisomeric derivatives, or by chiral column chromatography. Independent optical isomers such as salts with optically active acids are obtained from racemic salts by conventional methods and then crystallized.
  • Prodrugs and solvates of the compounds of the invention are also contemplated.
  • the term "prodrug” refers to a compound that undergoes a chemical reaction through metabolic or chemical methods based on the administered receptor to produce a compound of formula I, and / or a salt and / or a solvate thereof. Any compound that is transformed in vivo to provide a biologically active agent (ie, a compound of Formula I) is a prodrug within the scope and spirit of the invention.
  • a compound containing a carboxyl group can form a physiologically hydrolyzable ester as a prodrug, which is hydrolyzed in vivo to produce a compound of formula I itself.
  • prodrugs are preferably administered orally, since hydrolysis under many conditions occurs substantially under the influence of digestive enzymes.
  • Parenteral administration can be used, and the esters are themselves active, in those instances, hydrolysis occurs in the blood.
  • physiologically hydrolyzed esters of compounds of formula I include C 1-6 alkylbenzyl, 4-methoxybenzyl, indanyl, phthaloyl, methoxymethyl, C 1-6 alkanoyloxy -C 1-6 alkyl such as acetoxymethyl, pivaloyloxymethyl or propoxymethyl, C 1-6 alkoxycarbonyloxy-C 1-6 alkyl, such as methoxycarbonyl-oxymethyl Or ethoxycarbonyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl, (5-methyl-2-oxo-1,3-dioxolene-4-yl ) -Methyl and other well-known physiologically hydrolyzed esters, such as in the fields of pen
  • “Pharmaceutically acceptable carrier” generally refers to those generally accepted in the art that can deliver biologically active agents to animals, especially mammals. Formulating a pharmaceutically acceptable carrier is based on a number of factors well known to those of ordinary skill in the art. These include without limitation the type and nature of the active agent being formulated; the recipient to which the agent-containing composition is administered; the route of administration of the composition; and targeted therapy instructions. Pharmaceutically acceptable carriers include aqueous and non-aqueous liquid vehicles, as well as a variety of solid and semi-solid dosage forms. These carriers include many different components and additives. In addition to the active agent, these additional components are included in the formulation for a variety of reasons, such as the stability of active agents, adhesives, etc., which are well known to those of ordinary skill in the art. of.
  • the compounds of formula I of the invention may be administered in any suitable manner for the treatment of symptoms, depending on the amount of site-specific treatment or delivery of drug. Local administration is usually preferred for systemic treatment of skin-related diseases, cancerous or precancerous symptoms, but other modes of delivery are also considered.
  • the compounds are administered orally, such as in the form of tablets, capsules, granules, powders or liquid formulations including syrups; topically, such as in solutions, suspensions, gels or ointments; sublingual administration; cheek ground; parenteral administration Medicines such as by subcutaneous, intravenous, intramuscular or intrasternal injection or perfusion (such as sterile water or non-aqueous solution or suspension); nasal, such as by inhalation spray; topically, such as in the form of an emulsion or ointment; Such as in the form of suppositories; or liposomes.
  • Dosage unit formulations containing non-toxic, pharmaceutically acceptable excipients or diluents can be administered.
  • the compounds may be administered in an immediate or delayed release form. Immediate or delayed release can be obtained with suitable pharmaceutical compositions, in the case of partially delayed release, using equipment such as a subcutaneous graft or an osmotic pump.
  • compositions for oral administration include suspensions, which may contain, for example, microcrystalline cellulose for transmission, alginic acid or sodium alginate as a suspending agent, methyl cellulose as a viscosity enhancer, and the prior art Known sweeteners or flavors; immediate release tablets may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and / or lactose and / or other excipients, binders Bulking agents, disintegrating agents, diluents and lubricants are those known in the art.
  • the compounds of the present invention can also be delivered orally by sublingual and / or buccal administration, such as compression molding, compressed or lyophilized tablets.
  • compositions may include fast-dissolving diluents such as mannitol, lactose, sucrose, and / or cyclodextrins. Included in these formulations can also be high molecular weight excipients such as cellulose Or polyethylene glycol (PEG); excipients that aid mucosal adhesion such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (SCMC), and / or Maleic anhydride copolymer (e.g. ); And controlled release agents such as polyacrylic acid copolymers (such as ). Lubricants, glidants, perfumes, colorants and stabilizers can also be added to aid preparation and use.
  • PEG cellulose Or polyethylene glycol
  • HPMC hydroxypropyl cellulose
  • HPMC hydroxypropyl methyl cellulose
  • SCMC sodium carboxymethyl cellulose
  • compositions for spray or inhalation administration include solutions which may contain benzyl alcohol or other suitable preservatives, absorption enhancers that enhance absorption and / or biological activity, and / or other soluble or dispersing agents Such as those known in the art.
  • compositions for parenteral administration include injectable solutions or suspensions, which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Green's solution , Isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids including oleic acid.
  • suitable non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Green's solution , Isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids including oleic acid.
  • compositions for rectal administration include suppositories, which may contain, for example, suitable non-irritating excipients, such as cocoa butter, synthetic glycerides or polyvinyl glycols, which are solid at ordinary temperatures, but dissolve and / Or dissolve into the stomach and release the drug.
  • suitable non-irritating excipients such as cocoa butter, synthetic glycerides or polyvinyl glycols, which are solid at ordinary temperatures, but dissolve and / Or dissolve into the stomach and release the drug.
  • a therapeutically effective amount of a compound of the invention can be determined by one of ordinary skill in the art and includes, for mammals, exemplary doses from about 0.05 to 1000 mg / kg; 1-1000 mg / kg; 1-50 mg / kg; 5-250 mg / kg 250-1000 mg / kg, depending on the amount of active compound per kilogram of body weight per day, which can be administered in a single dose or in separate divided doses, such as from 1 to 4 times per day.
  • the particular dosage level and frequency of the agent for a particular receptor can alter the disease depending on a number of factors, including the activity of the particular compound used, the metabolic stability and length of the effect of the compound, race, age, weight, general health Condition, recipient gender and diet, mode and timing of administration, excretion rate, drug combination, and severity of particular disease.
  • Preferred recipients for treatment include animals, most preferably mammals such as humans and poultry animals such as dogs, cats, horses and the like.
  • a stirrer was added to a 25 mL test tube, and 0.4 mmol of 2-phenylindolizine (1a), 0.2 mmol of propyl mercaptan (2a), 0.04 mmol of HOAc, 0.01 mmol of CuI, 0.4 mmol of TBHP, and 2 mL of DMSO were added.
  • the reaction was stirred in a 60 ° C oil pan, and the reaction was monitored by a thin layer chromatography plate until 1a was consumed and the reaction was stopped.
  • the reaction mixture was then diluted with ethyl acetate and water, and extracted, and the ethyl acetate layer was taken. The organic layer was washed with brine, dried over Mg 2 SO 4 and evaporated under reduced pressure.
  • the crude mixture was purified by thin-layer chromatography on a silica gel plate.
  • Example 2 In a manner similar to the preparation of Example 1, the following compounds were prepared using only different raw materials.
  • mice Healthy Kunming mice were selected and provided by the Experimental Center of Guangdong Pharmaceutical University. Mice were housed in non-toxic plastic boxes of five females and males in separate cages. They changed litter once a day, fed and drank freely, kept at room temperature of 18-20 ° C, and exposed to natural light. The drug was dissolved in a 0.9% sodium chloride aqueous solution, and the dose of the test substance was expressed in mg / kg. The following doses are administered intraperitoneally, with a volume of 0.1 mL / 10g, and the doses are as follows: 50, 100, 150, 200, 300 mg / kg.
  • mice After the administration, the animals' appearance, spirit, diet, sleep, activity and daily death distribution were observed and recorded daily for 10 consecutive days, and the LD50 was calculated according to the Bliss method. After administration in the high-concentration group, the mice were debilitated, their feces were not formed before death, they were thin, their hairs were vertical, and their clumps atrophied.
  • the compounds of formula I according to the invention have lower toxicity.
  • inhibition rate (%) (absorbance value of control group-absorbance value of administration group) / (absorbance value of control group-absorbance value of blank group) x 100%.
  • the IC 50 calculation software (China Pharmaceutical University) was used to calculate the half inhibitory concentration (IC 50 ).
  • the unit of data in the table is ⁇ mol / L.
  • Experimental tumor strains include human gastric cancer cells BGC, human cervical adenocarcinoma cells HeLa, human colon cancer cells HCT116, human lung adenocarcinoma cells A549, human lung cancer cells NCI-H460, human prostate cancer cells DU-145, and human breast cancer cells MDA- MB-231. Cells were purchased from the cell bank of the Guangdong Provincial Center for Microbial Strains. The experimental results are shown in the following table.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé d'indolizine thiolisé à activité anticancéreuse et son dérivé. Ledit composé et son dérivé de formule (I) ont un effet inhibiteur sur une pluralité de cancers et de néoplasmes.
PCT/CN2018/000246 2018-06-07 2018-07-04 Composé d'indolizine thiolisé à activité anticancéreuse et son dérivé WO2019232665A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810583904.XA CN108640916A (zh) 2018-06-07 2018-06-07 一类具有抗癌活性的硫代吲嗪类化合物及其衍生物
CN201810583904.X 2018-06-07

Publications (1)

Publication Number Publication Date
WO2019232665A1 true WO2019232665A1 (fr) 2019-12-12

Family

ID=63751896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/000246 WO2019232665A1 (fr) 2018-06-07 2018-07-04 Composé d'indolizine thiolisé à activité anticancéreuse et son dérivé

Country Status (2)

Country Link
CN (1) CN108640916A (fr)
WO (1) WO2019232665A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458580A (zh) * 2009-04-21 2012-05-16 诺瓦提斯公司 作为mek抑制剂的杂环化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458580A (zh) * 2009-04-21 2012-05-16 诺瓦提斯公司 作为mek抑制剂的杂环化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLONNA, MARTINO ET AL.: "Electron-transfer Processes. Trans-sulfenylation of Electron-rich Systems with Sulfenamides", GAZZETTA CHIMICA ITALIAN A, vol. 116, no. 8, 31 December 1986 (1986-12-31), pages 449 - 452 *
LI, BIN ET AL.: "Transition-Metal-Free Regioselective Cross-Coupling: Controlled Synthesis of Mono- or Dithiolation Indolizines", ORG. LETT., vol. 20, 22 May 2018 (2018-05-22), pages 3291 - 3295, XP055667249 *
MIREK, JULIAN ET AL.: "The Reaction of Indolizines and Acetylindolizines with Trifluoromethylsulfenyl Chloride", JOURNAL OF FLUORINE CHEMISTRY, vol. 19, no. 1, 31 December 1981 (1981-12-31), pages 67 - 70, XP001028549, DOI: 10.1016/S0022-1139(00)85240-9 *

Also Published As

Publication number Publication date
CN108640916A (zh) 2018-10-12

Similar Documents

Publication Publication Date Title
US7005538B1 (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
CN105153188B (zh) 抗纤维化剂的稠环类似物
US9862721B2 (en) Tetrahydrocarboline derivative
BR112012007828B1 (pt) compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase
WO1999020620A1 (fr) Derive d'isoquinoleine et medicament
TW200906825A (en) Inhibitors of protein kinases
EA011707B1 (ru) Лекарственное средство для лечения нейродегенеративных заболеваний
JPH10182583A (ja) 新規ヒドロキサム酸誘導体
JP2005232179A (ja) ３−フェニルスルホニル−３，７−ジアザビシクロ［３，３，１］ノナン−化合物を含有する抗不整脈剤
CN112047944A (zh) 一种选择性抑制激酶化合物及其用途
CN107162982B (zh) 一类具有抗癌活性的咪唑类化合物及其衍生物
WO2019232662A1 (fr) Composé d'indolizine à activité anticancéreuse et son dérivé
WO2006007794A1 (fr) Derives de stilbene cis-1,2-substitues et utilisation de ceux-ci pour la preparation de medicaments servant au traitement ou a la prevention du diabete
CN107325052B (zh) 一类具有抗癌活性的咪唑酯类化合物及其衍生物
CN108658907B (zh) 一类具有消炎免疫活性的磺酰基取代呋喃类化合物及其衍生物
WO2019232665A1 (fr) Composé d'indolizine thiolisé à activité anticancéreuse et son dérivé
WO2019232663A1 (fr) L'invention concerne un composé d'indolizine amino-substitué à activité anticancéreuse et son dérivé.
EP2781508B9 (fr) Composés cycliques condensés contenant de l'azote pour utilisation en tant qu'antagonistes du crth2
JP2023511679A (ja) 二置換アダマンチル誘導体、その薬学的に許容される塩、およびこれを有効成分として含む癌の増殖抑制用薬学的組成物
JP5641054B2 (ja) 新規化合物、並びに、キネシンスピンドルタンパク質阻害剤及びその応用
WO2024077292A2 (fr) Synthèse de conjugués d'ains utilisés en tant qu'agents anti-inflammatoires et analgésiques à l'aide de l'approche d'hybridation moléculaire
CN109705120A (zh) 一类咪唑并[1,2-a]吡啶化合物及其制备方法和用途
PT92796A (pt) Processo para a preparacao de derivados da tioformamida e de composicoes farmaceuticas que os contem
CN114920697A (zh) 杂环基取代的茚满丙酰胺类化合物及其应用
JPH0625184B2 (ja) 新規置換ベンゾチアゾリノン、その製法およびそれを含有する医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18921333

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18921333

Country of ref document: EP

Kind code of ref document: A1